Date of Original Version
On December 8, 2016, the New England Journal of Medicine published a sounding board on Real World Evidence (RWE)1 by the US Food and Drug Administration (FDA) leadership. While the value of RWE based on nonrandomized observational studies was appreciated, such as for hypothesis generating, safety, and measuring quality in healthcare delivery, the authors expressed concerns on the quality of data sources and the ability of methodologies to control for confounding. In response, we offer a few considerations regarding these concerns.
Yuan, H., Ali, M.S., Brouwer, E.S., Girman, C.J., Guo, J.J., Lund, J.L., & Bennett, D.(2018), Real-World Evidence: What It Is and What It Can Tell Us According to the International Society for Pharmacoepidemiology (ISPE) Comparative Effectiveness Research (CER) Special Interest Group (SIG). Clin. Pharmacol. Ther., 104(2), 239-241. https://doi.org/10.1002/cpt.1086 Available at: https://doi.org/10.1002/cpt.1086